Mannatech, Incorporated

MTEX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-15.2M $2.5M $-2.2M $-4.5M $9.8M $6.3M $3.3M $-3.9M
Depreciation & Amortization $1.1M $1.5M $1.6M $1.6M $1.7M $2.0M $2.1M $2.1M
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $379.0K $291.0K $278.0K $337.0K $260.0K $334.0K $734.0K $1.1M
Net Cash from Operating Activities $-3.0M $2.3M $-2.4M $-2.6M $10.8M $6.0M $4.9M $-222.0K
Investing Activities
Capital Expenditures $1.4M $297.0K $748.0K $1.1M $650.0K $949.0K $1.2M $2.3M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-1.4M $-285.0K $-747.0K $-1.1M $-650.0K $-947.0K $-1.2M $-2.3M
Financing Activities
Dividends Paid — $0 $748.0K $1.5M $4.3M $3.4M $1.2M $3.1M
Stock Repurchases — $0 $176.0K $2.0M $5.1M $5.9M $294.0K $7.5M
Net Cash from Financing Activities $-561.0K $2.0M $-1.9M $-4.3M $-9.3M $-9.9M $-2.7M $-12.1M
Net Change in Cash $-5.5M $3.1M $-5.8M $-10.4M $-1.9M $-3.5M $416.0K $-16.2M
Free Cash Flow $-4.3M $2.0M $-3.1M $-3.7M $10.1M $5.1M $3.7M $-2.6M
← Newer Page 1 of 3 Older →